Enanta Pharmaceuticals Announces Fiscal Q4 and Full-Year 2026 Financial Results

Enanta Pharmaceuticals Reports Fiscal 2026 Financial Results and Highlights Progress Across RSV and Immunology Development Programs

Enanta Pharmaceuticals, a clinical-stage biotechnology company focused on developing small-molecule medicines for viral infections and immunological diseases, has reported its financial results for the fourth quarter and full fiscal year ended September 30, 2026. Alongside its financial performance, the company provided updates on its clinical development programs, highlighting continued progress in respiratory syncytial virus (RSV) treatment research and its expanding portfolio of oral immunology candidates.

During fiscal 2026, Enanta advanced its lead RSV candidate, zelicapavir, through two important clinical studies. The company completed enrollment in LOTUS, a Phase 2b trial evaluating zelicapavir in pediatric patients with RSV, and initiated dosing in RESOLVE, a Phase 2b/3 study investigating the candidate in adults at high risk of developing severe RSV disease. Topline results from the pediatric study are expected in the first quarter of 2027, while data from the Phase 2b portion of RESOLVE are anticipated during 2027.

The company also continued advancing its immunology pipeline, which is focused on developing potent and selective oral medicines targeting important drivers of immune-mediated inflammatory diseases. Key upcoming milestones include the completion of dosing in the Phase 1 study of EDP-978 by the end of 2026, an investigational new drug (IND) filing for EDP-903 in the second quarter of 2027, and an IND filing for EPS-5336 in the fourth quarter of 2027.

Jay R. Luly, Ph.D., President and Chief Executive Officer of Enanta Pharmaceuticals, said the company made significant progress across both its virology and immunology portfolios during fiscal 2026.

He highlighted the completion of enrollment in the LOTUS study and the initiation of RESOLVE as important steps in the clinical development of zelicapavir. According to Dr. Luly, the company believes the candidate has the potential to address an important unmet medical need among high-risk adult and pediatric populations, particularly given the absence of approved antiviral therapies specifically available to treat RSV.

Dr. Luly also emphasized the company’s commitment to developing potentially best-in-class oral medicines for immune-mediated diseases. With several clinical and regulatory milestones expected in the coming quarters, Enanta anticipates multiple development catalysts during the first half of 2027.

Fiscal Fourth Quarter and Full-Year 2026 Financial Performance

Enanta reported total revenue of $12.9 million for the three months ended September 30, 2026, compared with $15.1 million in the corresponding period of fiscal 2025. Revenue for the fourth quarter of 2026 consisted of royalty income generated from worldwide net sales of AbbVie’s hepatitis C virus (HCV) treatment regimen MAVYRET®/MAVIRET® (glecaprevir/pibrentasvir).

For the full fiscal year ended September 30, 2026, total revenue reached $63.0 million, compared with $65.3 million for the same period in 2025. The decreases in both quarterly and annual revenue were primarily attributable to lower sales of MAVYRET/MAVIRET by AbbVie.

A portion of Enanta’s ongoing royalty revenue from AbbVie’s net sales of MAVYRET/MAVIRET is subject to a royalty sale transaction with OMERS, one of Canada’s largest defined benefit pension plans. Under the transaction, 54.5% of the royalties earned after June 2023 are payable to OMERS.

For accounting purposes, Enanta treated the transaction as debt and recorded the $200.0 million upfront purchase payment as a liability. The company recognizes 100% of the royalty revenue earned each quarter and subsequently amortizes the associated debt liability as 54.5% of the cash royalty payments are transferred to OMERS.

These payments are scheduled to continue through June 30, 2032, subject to a payment cap of 1.42 times the original purchase price. Once the applicable cap is reached, Enanta will retain 100% of the cash royalty payments.

Interest expense associated with this arrangement and other financial obligations increased during fiscal 2026. The company recorded interest expense of $3.5 million in the fourth quarter of 2026, compared with $2.4 million in the fourth quarter of 2025. For the full year, interest expense increased to $14.1 million from $7.7 million in fiscal 2025.

The increase in interest expense was attributed to higher forecasted royalty revenue from AbbVie’s MAVYRET/MAVIRET sales during the first half of Enanta’s 2026 fiscal year.

Research and Development Investment Reflects Clinical Program Priorities

Research and development expenses totaled $26.1 million for the three months ended September 30, 2026, compared with $23.8 million in the corresponding quarter of 2025.

The increase in quarterly research and development spending primarily reflected higher clinical trial costs associated with Enanta’s RSV programs. In particular, expenses increased as the company continued conducting the LOTUS and RESOLVE studies of zelicapavir.

For the full fiscal year 2026, research and development expenses were $88.5 million, compared with $106.7 million in fiscal 2025. The year-over-year reduction was mainly attributable to the timing of clinical trial expenses associated with the RSV portfolio, partially offset by increased investment in the company’s immunology programs.

The financial results reflect Enanta’s continued investment in advancing its clinical-stage pipeline while managing spending across multiple therapeutic areas.

General and administrative expenses were $8.8 million for the fourth quarter of fiscal 2026, compared with $9.7 million for the same period in 2025. For the full year, these expenses declined to $36.8 million from $43.9 million.

The decrease in general and administrative costs during both periods was primarily driven by lower stock-based compensation expenses and reduced legal expenses related to the company’s patent infringement litigation against Pfizer.

Interest and investment income, net, totaled $1.8 million in the fourth quarter of 2026, compared with $2.1 million in the fourth quarter of 2025. For the full fiscal year, interest and investment income declined to $8.2 million from $9.4 million. The reduction was primarily associated with lower interest rates.

Enanta recorded an income tax benefit of less than $0.1 million for the fourth quarter of 2026, compared with an income tax expense of less than $0.1 million in the corresponding quarter of 2025. For the full fiscal year, the company recorded an income tax expense of less than $0.1 million, compared with an income tax benefit of $1.7 million in fiscal 2025. The earlier-period tax benefit was primarily related to interest earned on a federal income tax refund received during fiscal 2025.

Net Loss and Cash Position

Enanta reported a net loss of $23.7 million for the three months ended September 30, 2026, equivalent to a loss of $0.81 per diluted common share. This compared with a net loss of $18.7 million, or $0.87 per diluted common share, in the fourth quarter of fiscal 2025.

For the full fiscal year 2026, the company’s net loss was $68.2 million, or $2.35 per diluted common share, compared with a net loss of $81.9 million, or $3.84 per diluted common share, in fiscal 2025.

The improvement in the full-year net loss reflects the company’s financial performance during the year, including lower annual research and development and general and administrative expenses.

As of September 30, 2026, Enanta held $194.5 million in cash, cash equivalents, and marketable securities.

The company expects its existing financial resources, together with the portion of future royalty revenue it retains from AbbVie’s MAVYRET/MAVIRET sales, to be sufficient to support the anticipated cash requirements of its existing business operations and development programs into fiscal 2029.

Virology Pipeline: Advancing Zelicapavir for RSV

Enanta’s virology portfolio includes two clinical-stage RSV treatment candidates: zelicapavir, a once-daily N-protein inhibitor, and EDP-323, a once-daily L-protein inhibitor. Both candidates have received Fast Track designation from the U.S. Food and Drug Administration (FDA).

RSV is a common respiratory virus that can cause mild, cold-like symptoms but may lead to serious respiratory illness in certain populations. Infants, young children, older adults, and individuals with underlying health conditions can face an increased risk of severe disease and complications.

Despite the significant clinical burden associated with RSV, treatment options remain limited, particularly for antiviral therapies intended to directly target the virus. Enanta is developing its candidates to address this unmet need and potentially provide new treatment approaches for vulnerable patient groups.

LOTUS Phase 2b Pediatric Trial Completes Enrollment

Enanta announced that enrollment has been completed in LOTUS, its Phase 2b clinical trial evaluating zelicapavir in pediatric patients with RSV.

The study is designed to assess the candidate’s clinical efficacy, safety, and antiviral activity. Its primary evaluation focuses on the time required for complete resolution of RSV signs and symptoms, measured using the RESOLVE-P clinical scoring scale.

The trial will provide information on whether treatment with zelicapavir can help improve the course of RSV illness in the pediatric population. Safety and antiviral activity assessments will also contribute to understanding the candidate’s potential role in treating children with the infection.

Enanta expects to report topline results from LOTUS in the first quarter of 2027. The anticipated data will represent an important milestone in the company’s efforts to expand zelicapavir development beyond adult populations.

RESOLVE Phase 2b/3 Study Evaluates High-Risk Adults

Enanta has also initiated patient dosing in RESOLVE, a Phase 2b/3 clinical trial investigating zelicapavir in adults at high risk of developing severe RSV disease.

The study is targeting populations that may be particularly vulnerable to serious RSV-related complications, including adults aged 75 years and older and individuals with underlying conditions such as chronic obstructive pulmonary disease (COPD) or congestive heart failure.

The trial is designed to evaluate the time to complete resolution of 13 RSV symptoms, measured using the RiiQ™ assessment tool. Secondary endpoints include changes in hospitalization rates, additional clinical efficacy measures, virological outcomes, and safety.

The Phase 2b portion of RESOLVE is expected to provide initial clinical information on zelicapavir’s potential effectiveness and safety in high-risk adults. Enanta anticipates reporting topline results from this portion of the study during 2027.

The progression of RESOLVE, alongside the completed enrollment in LOTUS, reflects the company’s strategy to investigate zelicapavir across two important patient populations. If successful, the development program could support further evaluation of the candidate as a potential treatment option for patients at increased risk of severe RSV disease.

Immunology Portfolio Advances with Three Development Programs

In addition to its virology pipeline, Enanta is building an immunology portfolio focused on developing highly potent and selective oral inhibitors for inflammatory diseases. The programs are designed to target important biological pathways involved in type 2 immune responses and mast cell-driven conditions.

The company’s current immunology pipeline includes EDP-978, an oral KIT inhibitor; EDP-903, an oral STAT6 inhibitor; and EPS-5336, a development candidate targeting MRGPRX2.

EDP-978: Oral KIT Inhibitor for Chronic Urticaria

EDP-978 is Enanta’s lead immunology candidate and is being developed as a potent and selective, once-daily oral KIT inhibitor.

The candidate is initially being investigated for chronic urticaria, a condition characterized by recurring hives and itching, and may also have potential in other mast cell-mediated diseases.

KIT is a receptor involved in mast cell development, survival, and function. By inhibiting KIT, Enanta aims to develop a treatment approach that could address biological mechanisms associated with mast cell activity.

A randomized, double-blind, placebo-controlled, first-in-human Phase 1 clinical trial of EDP-978 is ongoing. The study is designed to evaluate the candidate’s safety and other early clinical characteristics.

Enanta expects to complete dosing in the trial by the end of 2026 and now anticipates reporting topline results in the first quarter of 2027.

The upcoming data will provide an initial assessment of EDP-978 in humans and help guide the next stages of its clinical development.

EDP-903: STAT6 Inhibitor for Atopic Dermatitis

The company’s second immunology candidate, EDP-903, is a potent and selective oral STAT6 inhibitor being developed for atopic dermatitis and other diseases currently treated with dupilumab.

STAT6 is an important signaling protein involved in type 2 inflammation. Inhibiting this pathway represents a potential strategy for addressing inflammatory conditions driven by type 2 immune responses.

Enanta has completed IND-enabling activities for EDP-903. However, a delay in drug manufacturing has affected the anticipated regulatory timeline.

The company now expects to file an IND for EDP-903 in the second quarter of 2027. Following the planned submission, the candidate could advance toward clinical evaluation, subject to the applicable regulatory process.

EPS-5336: New MRGPRX2 Development Candidate

Enanta has selected EPS-5336 as its development candidate for its third immunology program, which targets Mas-related G-protein-coupled receptor member X2 (MRGPRX2).

MRGPRX2 is a non-canonical G-protein-coupled receptor expressed predominantly on mast cells and also found in peripheral neurons. The receptor is involved in signaling processes associated with mast cell activation.

Enanta believes that inhibiting MRGPRX2 could offer a potential treatment approach for multiple mast cell-driven diseases, as well as migraine.

EPS-5336 has demonstrated potent inhibition of MRGPRX2 signaling in both in vitro and in vivo studies. In cellular assays, the compound showed sub-nanomolar potency, with an EC50 ranging from 0.2 to 0.6 nanomolar, through a preferred noncompetitive mechanism of inhibition.

In humanized MRGPRX2 mouse models, EPS-5336 prevented skin mast cell activation. The compound also demonstrated activity across multiple MRGPRX2 agonists and inhibited MRGPRX2-induced degranulation in meningeal mast cells relevant to migraine research.

The candidate has also shown high selectivity for MRGPRX2 compared with other G-protein-coupled receptors. In addition, its in vitro and in vivo absorption, distribution, metabolism, and excretion (ADME) properties have been described as favorable and supportive of its potential for once-daily dosing.

Enanta expects to file an IND for EPS-5336 in the fourth quarter of 2027. The planned submission represents a key milestone in advancing the program toward potential clinical development.

Corporate Updates: Leadership Transition and Operational Changes

Enanta also provided several corporate updates during its fiscal 2026 reporting period.

In October 2026, the company announced that Jay R. Luly, Ph.D., would retire as President and Chief Executive Officer by February 1, 2027, following 23 years of leadership at Enanta.

The company’s Board of Directors has initiated a comprehensive search for his successor, considering both internal and external candidates. Dr. Luly is expected to continue serving as a strategic advisor for the remainder of 2027 to support an orderly leadership transition.

Enanta also appointed Tara L. Kieffer, Ph.D., to the newly created position of Chief Operating Officer. Dr. Kieffer joined the company in 2020 after spending 16 years at Vertex Pharmaceuticals, where she held roles across research, clinical development, integrated program management, and business development. Most recently, she served as Enanta’s Chief Product Strategy Officer.

In September 2026, Enanta completed a strategic assessment of its resource allocation and operating structure to align its operations with current priorities and long-term objectives. Following the review, the company implemented targeted workforce reductions across the organization, reducing its workforce by approximately one-third.

The changes were intended to improve operational efficiency, concentrate resources on the company’s highest-priority development opportunities, and extend financial flexibility.

Patent Litigation and Upcoming Investor Conferences

Enanta also provided an update regarding its patent infringement dispute with Pfizer Inc.

In August 2025, the company filed an action in the Unified Patent Court (UPC) of the European Union concerning European Patent No. EP 4 051 265, referred to as the ‘265 Patent. The action alleged infringement in connection with Pfizer’s manufacture, use, and sale of Paxlovid™ (nirmatrelvir tablets; ritonavir tablets) in the 18 EU member states participating in the UPC.

Pfizer filed a counterclaim seeking revocation of the patent. A hearing addressing the infringement action and the revocation counterclaim took place in September 2026.

In October 2026, the UPC issued its decision, concluding that the ‘265 Patent was invalid. The court also determined that Enanta’s infringement action was unfounded in light of its finding on patent validity.

Separately, Pfizer had filed an opposition proceeding against the patent with the European Patent Office (EPO). The EPO has scheduled a hearing in that proceeding for April 2027.

Enanta is also scheduled to participate in upcoming investor and healthcare industry conferences. The company will present at the Jefferies Global Healthcare Conference in London on November 18, 2026, followed by the 9th Annual Evercore Healthcare Conference on December 2, 2026.

The company plans to release its fiscal first-quarter 2027 financial results on February 8, 2027.

Multiple Development Milestones Expected in 2027

Enanta enters fiscal 2027 with several important clinical and regulatory milestones across its virology and immunology portfolios. In RSV, the company expects topline results from the pediatric LOTUS study in the first quarter of 2027 and data from the Phase 2b portion of RESOLVE during the year.

In immunology, the company anticipates reporting Phase 1 data for EDP-978 in the first quarter of 2027, filing an IND for EDP-903 in the second quarter, and submitting an IND for EPS-5336 in the fourth quarter.

These programs represent the company’s strategy to develop small-molecule medicines targeting viral infections and immune-mediated diseases. With $194.5 million in cash, cash equivalents, and marketable securities at the end of fiscal 2026, Enanta expects its available resources and retained royalty revenue to fund its existing operations and development programs into fiscal 2029.

As the company moves through its leadership transition and continues to prioritize its pipeline, the upcoming clinical and regulatory milestones will be important indicators of progress toward its longer-term development objectives.

About Enanta Pharmaceuticals, Inc.

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for viral infections and immunological diseases. In virology, Enanta’s clinical programs are focused on the development of first-in-disease and best-in-disease treatments for respiratory syncytial virus (RSV). The Company’s immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, with KIT, STAT6 and MRGPRX2 inhibition.

Glecaprevir, a protease inhibitor discovered by Enanta, is part of the only treatment approved for curing both acute and chronic hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta’s operations.

Source Link

Newsletter Updates

Enter your email address below and subscribe to our newsletter